首页> 外文期刊>Diabetes >Baroreflex Sensitivity Impairment During Hypoglycemia: Implications for Cardiovascular Control
【24h】

Baroreflex Sensitivity Impairment During Hypoglycemia: Implications for Cardiovascular Control

机译:低血糖期间的压力反射敏感性受损:对心血管控制的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Studies have shown associations between exposure to hypoglycemia and increased mortality, raising the possibility that hypoglycemia has adverse cardiovascular effects. In this study, we determined the acute effects of hypoglycemia on cardiovascular autonomic control. Seventeen healthy volunteers were exposed to experimental hypoglycemia (2.8 mmol/L) for 120 min. Cardiac vagal baroreflex function was assessed using the modified Oxford method before the initiation of the hypoglycemic-hyperinsulinemic clamp protocol and during the last 30 min of hypoglycemia. During hypoglycemia, compared with baseline euglycemic conditions, 1) baroreflex sensitivity decreases significantly (19.2 ± 7.5 vs. 32.9 ± 16.6 ms/mmHg, P < 0.005), 2) the systolic blood pressure threshold for baroreflex activation increases significantly (the baroreflex function shifts to the right; 120 ± 14 vs. 112 ± 12 mmHg, P < 0.005), and 3) the maximum R-R interval response (1,088 ± 132 vs. 1,496 ± 194 ms, P < 0.001) and maximal range of the R-R interval response (414 ±128 vs. 817 ± 183 ms, P < 0.001) decrease significantly. These findings indicate reduced vagal control and impaired cardiovascular ho-meostasis during hypoglycemia.
机译:研究表明,低血糖暴露与死亡率增加之间存在关联,从而增加了低血糖具有不利心血管作用的可能性。在这项研究中,我们确定了低血糖对心血管自主控制的急性作用。 17名健康志愿者暴露于实验性低血糖(2.8 mmol / L)中120分钟。在开始降血糖-高胰岛素钳夹方案之前以及在低血糖的最后30分钟期间,使用改良的Oxford方法评估心脏迷走神经压力反射功能。在低血糖期间,与基线正常血糖状况相比,1)压力反射敏感性显着降低(19.2±7.5与32.9±16.6 ms / mmHg,P <0.005),2)压力反射激活的收缩压阈值显着增加(压力反射功能转移)右侧; 120±14 vs. 112±12 mmHg,P <0.005),和3)最大RR间隔响应(1,088±132 vs. 1,496±194 ms,P <0.001)和RR间隔响应的最大范围(414±128 vs. 817±183 ms,P <0.001)明显降低。这些发现表明在低血糖症中迷走神经控制降低和心血管血流动力学受损。

著录项

  • 来源
    《Diabetes》 |2016年第1期|209-215|共7页
  • 作者单位

    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Temple University School of Medicine, Philadelphia, PA;

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;

    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;

    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号